Tier 4 — mechanistic

Inflammation and Stem Cells in Diabetic and Chronic Kidney Disease

LaTonya J. Hickson
ClinicalTrials.gov trial registry record 2017

Bibliography

Trial registry
View on ClinicalTrials.gov Registered trial — results not yet published in a peer-reviewed journal.
Funding
Sponsor: Mayo Clinic. The study was suspended because of lack of funding.
Competing interests
Not reported in the registry record.

Study snapshot

DesignPhase 2 interventional study evaluating short-course fisetin in diabetic/chronic kidney disease.
ModelAdults aged approximately 40-80 years with advanced chronic kidney disease, including diabetic kidney disease.
SamplePublic 2026 reviews report approximately 26 participants enrolled before suspension.
InterventionFisetin approximately 20 mg/kg/day orally for two consecutive days.
DurationSingle short course with subsequent biomarker, stem-cell, kidney-function and physical-function assessments.
EndpointsAdipose-derived mesenchymal stem/stromal-cell function; Inflammatory markers including CRP; Kidney function; Physical function; Senescence-related measures

What the study showed, in plain terms

This Mayo Clinic study was designed to test whether a short fisetin course changes stem-cell function, inflammation, kidney-related outcomes and physical function in people with diabetic or chronic kidney disease.

The trial was suspended because of lack of funding and did not generate a completed fisetin efficacy dataset. It should therefore be treated as an interrupted clinical experiment, not evidence that fisetin benefits kidney disease.

Key findings

  • The planned fisetin exposure was approximately 20 mg/kg/day for two consecutive days.
  • The study targeted advanced chronic kidney disease and diabetic kidney disease.
  • The trial was suspended because of lack of funding.

What this study can and cannot tell us

  • Suspended before completing the planned program.
  • No completed efficacy evidence is available.
  • Kidney-disease populations have distinct medication and safety considerations that limit extrapolation to general supplement use.

Citation network

Articles citing this research paper

1 article

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology